The Role of Everolimus in the Treatment of Breast Cancer - Journal of Cancer Therapy

JCT > Vol.4 No.7, September 2013

The Role of Everolimus in the Treatment of Breast Cancer ()

HTML

Download as PDF (Size: 406KB) PP. 1167-1176

DOI: 10.4236/jct.2013.47136 6,886 Downloads 9,528 Views Citations

Author(s)

José Pablo Leone, Ricardo H. Álvarez

Affiliation(s)

Department of Breast Medical Oncology, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas, M. D. Anderson Cancer Center, Houston, USA..
University of Pittsburgh Cancer Institute, Pittsburgh, USA.

ABSTRACT

The development of resistance to chemotherapy, endocrine therapy and anti HER2 agents in breast cancer is an important and common problem that impacts in the management of patients, particularly in the metastatic setting. This resistance has been explained in part by the activation of signal transduction pathways, including the PI3K/AKT/mTOR. The blockade with mTOR inhibitors such as everolimus is a new target agent for therapy that attempts to enhance treatment efficacy and restore tumor sensitivity. In this review article, we present the data about the use of everolimus for the treatment of breast cancer in all tumor phenotypes. Future studies that evaluate biomarkers for treatment response are needed to identify the specific populations that have the highest benefit of this new targeted therapy.

KEYWORDS

Advanced Breast Cancer; Everolimus; mTOR Inhibitors

Share and Cite:

J. Leone and R. Álvarez, "The Role of Everolimus in the Treatment of Breast Cancer," Journal of Cancer Therapy, Vol. 4 No. 7, 2013, pp. 1167-1176. doi: 10.4236/jct.2013.47136.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies